The Latest Breaking News from Grail

Every company with acquisition plans in the U.S. and Europe should be concerned about the FTC partnering with EU regulators to sink the Illumina-Grail deal.

We put one of Canyon's fast and light gravel bikes to the test and see how it rides outside its comfort zone

Researchers believe the main cause for surging cancer rates is because humans are living longer. A new test is hoping to detect cancerous cells to allow for earlier treatment for the disease

Reuters EQT Corp Close To Buying THQ Appalachia

Wall Street Journal

One way to eliminate the competition in business is simply to buy them out and shut them down. And that means less choice for consumers and sometimes the loss of innovative and, in the case of the pharmaceutical industry, even life-saving products. But such so-called killer acquisitions are likely to…

Fresh off the Federal Trade Commission’s successful challenges to four hospital mergers, the Biden administration’s new majority on the commission is primed to more aggressively combat consolidation in the health care industry than it has in past years.

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

The event will be played on the Dinah Shore Tournament Course at Mission Hills Country Club.